BioArctic AB (BIOA_B) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much. Good morning and welcome to Biotic's presentation for the first quarter of 2025. Biotic has now entered a new era, an era of profitable growth, which is signified by an extraordinarily strong first quarter and a lot of activities throughout the different parts of the business. I will talk more about that in today's presentation and we take the next slide, please. I'm Gunilla Oswald, I'm the CEO of Biotic, and I will share today's presentation with our CFO, Anders Martin Lööf. Next slide, please. Biotic is listed at Nasdaq Stockholm large cap, and this is our disclaimer. Next slide, please. As I just said, Biotic has now entered a new era, an era of profitable growth with continuous and increasing royalties, also supported by milestones, which is reflecting the benefit of our successful partnership business model. This enables even further activities across the business as we develop new and better treatments for patients in an increasing number of severe brain disorders. Let's look at some of the highlights this year. First of all, Lekembe is now approved in all major markets, including US, Japan, China, and Europe. We see continued growth across markets and more and more patients are getting access to Lekembe. Continued development of more convenient dosing and more convenient diagnosis will continue to drive the growth going forward. We are very excited about the FDA recently approved the first blood test, which is used to diagnose Alzheimer's disease. So that means that even more patients will be able to be treated with Lecambi. I continue to be very excited about our brain transporter technology. The significant deal with Bristol Mild Squibs for our pyroglyph A-beta antibodies for Alzheimer's disease, including BAN 2803, which is utilizing our ...